phenanthro[9,10-c]thiophene | 235-95-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: phenanthro[9,10-c]thiophene
• CAS: 235-95-0
• 化学式: C₁₆H₁₀S
• 分子量: 234.321
• InChiKey: LRRNXDMWYMXMHA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  phenanthro[9,10-c]thiophene 在 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.25h， 生成 1,3-bis(trimethylstannyl)phenanthro[9,10-c]thiophene
  参考文献：
  名称：

  由C ？序列模合成苯并[9,10-c]噻吩 H活化，铃木交叉偶联和光环化反应

  摘要：

  总共合成了15个不同的3,4-二芳基噻吩，它们在一个芳基取代基的邻位带有一个氯原子。通过氧化交叉偶联反应引入一个芳基，该反应涉及噻吩核的C4（3）处的CH活化。在大多数情况下，另一个芳基是通过铃木交叉偶联反应引入的，该反应是氧化交叉偶联步骤的后续步骤。3,4-二芳基噻吩的光环化反应是在苯和乙腈的混合溶剂中（50:50 v / v）在λ = 254 nm处进行的，标题化合物的收率为60-82％。在邻位确定光环化的选择性氯取代的芳基环由氯取代基的位置决定。在另一个环上，观察到一个单一的区域异构体的苯基和对位取代的苯基。对于2-萘基和邻位取代的苯环，人们明显倾向于主要的区域异构体，而苯环中的间位取代则导致5和7位取代的菲咯啉的比例约为1：1 [9,10] [ c ]噻吩。从机理上讲，光环化很可能发生在光化学允许的，旋转的[（4n + 2）π]过程中，并伴随着HCl的消除。显示了两个菲咯啉[9,10-

  DOI：

  10.1002/chem.201402765
• 作为产物：
  描述：

  3,4-二苯基噻吩 在 三氟甲磺酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以34%的产率得到phenanthro[9,10-c]thiophene
  参考文献：
  名称：

  由2,3-二氯-5,6-二氰基-1,4-苯醌（DDQ）促进的环氧化合成苯并[9,10-c]噻吩。

  摘要：

  已经开发了一种新的制备菲咯啉[9,10-c]噻吩的方法。在三氟甲磺酸存在下，3,4-二芳基噻吩经历了2,3-二氯-5,6-二氰基-1,4-苯醌（DDQ）促进的环氧化。NMR和计算研究表明，噻吩的质子化在该反应中起关键作用。该反应可用于制备菲[9,10-c]噻吩以及具有烷基，溴和甲氧基取代基的衍生物。但是，反应的产率和选择性取决于取代基的性质和位置。双（3-甲氧基苯基）噻吩在这些条件下反应以57％的收率得到所需的产物，而双（4-甲氧基苯基）噻吩没有产生产物。双（3-溴苯基）噻吩没有反应，但是双（4-溴苯基）噻吩的环氧化以34％的收率提供了所需的产物。

  DOI：

  10.1002/cplu.201900099

文献信息

• 9-Stannafluorenes: 1,4-Dimetal Equivalents for Aromatic Annulation by Double Cross-Coupling
  作者：Ikuhiro Nagao、Masaki Shimizu、Tamejiro Hiyama

  DOI：10.1002/anie.200903779

  日期：2009.9.28

  Double or nothing! A straightforward and high‐yielding approach to a variety of polycyclic aromatic hydrocarbons has been achieved through palladium‐catalyzed annulation of 9,9‐dimethyl‐9‐stannafluorenes and dithienostannole with 1,2‐dihaloarenes (see scheme). In addition, 1,1‐dibromo‐1‐alkenes can also be applied to this annulation to produce dibenzofulvenes in excellent yields.

  双倍或一无所有！通过钯催化的1,2-二卤代芳烃与9,9-二甲基-9-锡芴和二噻吩并环戊烷实现了直接，高产的多种多环芳烃方法。此外，还可以将1,1-二溴-1-烯用于该环合反应，以高收率生产二苯并富烯。
• Phenanthro[2,3-6]thiophene derivatives, pharmaceutical compositions and
  申请人：Burroughs Wellcome Co.

  公开号：US04910218A1

  公开（公告）日：1990-03-20

  The present invention relates to anti tumor compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（式（I）的化合物包括这些醚，总碳原子数不超过29）的抗肿瘤化合物；它们的醚，酯；酸加成盐；其中Ar是由5元环和6元环组成的融合四环芳香环系统，并含有至少一个杂原子和3个芳香环，总环原子数不超过18，或其取代衍生物；杂原子最好是氧、硫或氮；当它是氮时，被氢、甲基或乙基取代；R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14为氢、甲基、羟基或羟甲基。
• Benzo[c]curbazole derivatives, compositions and use
  申请人：Burroughs Wellcome Co.

  公开号：US04952597A1

  公开（公告）日：1990-08-28

  The present invention related to anti tumor compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteratom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的抗肿瘤化合物的公式（I）ArCH.sub.2R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，总共不超过29个碳原子）；醚，酯；其酸加成盐；其中Ar是由5个成员和6个成员的环组成的融合四环芳香环系统，并包含至少一个杂原子和3个芳香环，总环原子数不超过18个，或其取代衍生物；杂原子最好是氧，硫或氮；当它是氮时，它被氢，甲基或乙基取代；R.sup.1含有不超过八个碳原子，并且是一个组##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五个或六个成员的饱和碳环；R.sup.10是氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14是氢，甲基，羟基或羟甲基。
• Tetracyclic heterocyclic derivatives, pharmaceutical compositions and use
  申请人：Burroughs Wellcome Co.

  公开号：US04999369A1

  公开（公告）日：1991-03-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物式（I）ArCH.sub.2R.sup.1（I）或其单甲基或单乙基醚（式（I）的化合物包括这些醚，总碳原子数不超过29）；它们的醚，酯；酸加成盐；其中Ar是由5元环和6元环组成的融合四环芳香环系，含有至少一个杂原子和3个芳香环，环原子总数不超过18个，或其取代衍生物；杂原子最好是氧、硫或氮；当它是氮时，它被氢、甲基或乙基取代；R.sup.1含有不超过8个碳原子，是一个基团##STR1##其中m为0或1；R.sup.5是氢；R.sup.6和R.sup.7相同或不同，每个都是氢或C.sub.1-5烷基，可选地被羟基取代；R.sup.8和R.sup.9相同或不同，每个都是氢或C.sub.1-3烷基；##STR2##是一个五元环或六元环饱和碳环；R.sup.10是氢、甲基或羟甲基；R.sup.11、R.sup.12和R.sup.13相同或不同，每个都是氢或甲基；R.sup.14是氢、甲基、羟基或羟甲基。
• Benzo[c]carbazole propanediol compound and salts thereof
  申请人：Burroughs Wellcome Co.

  公开号：US04797495A1

  公开（公告）日：1989-01-10

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式(I) ArCH.sub.2 R.sup.1 (I)或其单甲基或单乙基醚（公式（I）包括这些醚，总共不超过29个碳原子）;它们的醚，酯;酸加成盐;其中Ar是由5个和6个成员环组成的融合四环芳香环系，包含至少一个杂原子和3个芳香环，总环原子数不超过18个，或其取代衍生物;杂原子最好是氧，硫或氮;当它是氮时，它被氢，甲基或乙基取代; R.sup.1含有不超过八个碳原子，是一个组##STR1##其中m为0或1; R.sup.5是氢; R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-5烷基，可选地被羟基取代; R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基; ##STR2##是一个五或六成员的饱和碳环; R.sup.10是氢，甲基或羟甲基; R.sup.11，R.sup.12和R.sup.13相同或不同，每个是氢或甲基; R.sup.14是氢，甲基，羟基或羟甲基。